Pharmacological conversion of atrial fibrillation in the patients of Graves' disease

Yo Kunii, Takashi Uruno, Masako Matsumoto, Koji Mukasa, Jaeduk Noh, Koichi Ito, Makoto Akaishi, Shingo Hori, Hiroe Nakazawa

研究成果: Article査読

6 被引用数 (Scopus)


Background: Hyperthyroidism is one of the common causes of atrial fibrillation (AF), and AF is associated with increased morbidity and mortality due to thromboembolism. The sinus rhythm maintenance rate of hyperthyroidism- induced AF patients after conversion to sinus rhythm is excellent. The present study was undertaken to assess the efficacy and safety of bepridil, a multichannel blocker, in patients with hyperthyroidism-induced persistent AF. Methods and Results: Sixty-two patients with hyperthyroidism-induced persistent AF were treated with bepridil. Oral bepridil therapy resulted in conversion to sinus rhythm in 32 (51.6%) of the 62 patients. There were no significant differences in clinical characteristics between the responders and non-responders. At the observation period of an average of 23.9 months, the sinus rhythm maintenance rate was found to be 81.3%. Adverse effects consisted of abnormal QTc prolongation in 3 patients and sinus bradycardia in 10 patients. There was one death in which a causal association with bepridil could not be ruled out. Conclusions: Bepridil is as beneficial treatment to convert AF for the patients with hyperthyroidism-induced persistent AF as it is for the patients with AF due to other causes. However, bepridil should be used with caution to avoid serious side effects.

ジャーナルTokai Journal of Experimental and Clinical Medicine
出版ステータスPublished - 2012 12月 1

ASJC Scopus subject areas

  • 医学(全般)


「Pharmacological conversion of atrial fibrillation in the patients of Graves' disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。